Prospective, Controlled Versus Placebo, Randomized, Double-blind Study, Evaluating the Value of Non-opioid Analgesic Combination (Based on Paracetamol, Nefopam, Ketoprofen) for Postoperative Analgesia.
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- 入组人数
- 223
- 试验地点
- 19
- 主要终点
- Morphine consumption (mg), accumulated over 24 hours, measured by patient controlled analgesia (PCA).
研究概览
简要总结
The combination of different analgesic drugs and/or analgesia techniques is part of the standard management of postoperative analgesia. The analysis of the literature reveals a lack of comparison of the associations of non-opioid analgesic (NOA) with morphine for postoperative analgesia.
The objectives of this study are :
- comparing the morphine sparing effect of different combination of 3 NOA (paracetamol, nefopam, ketoprofen) for postoperative analgesia.
- determining whether the morphine-sparing effect is associated with or without a reduction in the incidence of morphine side effects.
- evaluating the effects of NOA on postoperative hyperalgesia.
详细描述
Since the description of the concept of balanced analgesia in the early 90's, the combination of different analgesic drugs and/or analgesia techniques is part of the standard management of postoperative analgesia. A recent survey conducted in France by Fletcher et al. showed that patients often received one or more NOA associated with an opioid. The benefit and risk of the use of opioids associated with NOA were recently reassessed as part of a formal recommendation of experts and detailed in a recent review. The analysis of the literature reveals a lack of comparison of the combinations of NOA with morphine for postoperative analgesia. For example, paracetamol and morphine in combination does not always allow a significant morphine-sparing effect compared with morphine alone and does not reduce the incidence of morphine side effects. A number of definitive answers has therefore yet to be found: Does NOA -morphine association allow an effective morphine-sparing effect? Is there an interest in prescribing several NOAs in association? If yes, what are the most interesting combinations in terms of morphine-sparing effect and safety?
Another question concerns the effects of NOA on postoperative hyperalgesia. This hyperalgesia, which results from surgery-related inflammation, is increased by consumption of morphine and not only contributes to the overall experience of postoperative pain but also to the chronicisation of postoperative pain. Since in clinical practice, hyperalgesia can be measured using specific tools (Von Frey filament type), our study will evaluate the anti-hyperalgesic effects of NOA on a subgroup of patients enrolled in the centers used to evaluate nociceptive thresholds.
The objectives of this study are :
- comparing the morphine sparing effect of different combination of 3 NOA (paracetamol, nefopam, ketoprofen) for postoperative analgesia.
- determining whether the morphine-sparing effect is associated with or without a reduction in the incidence of morphine side effects.
- evaluating the effects of NOA on postoperative hyperalgesia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults older than 18 years
- •Receiving scheduled surgery requiring the use of a PCA to treat postoperative pain
- •Patients with a written informed consent
- •Patients with a written informed consent for the sub-study on hyperalgesia (patients in the centers concerned)
- •Affiliate to a social security system
排除标准
- •Allergy to morphine, paracetamol, nefopam or ketoprofen or to any of their excipients
- •Absorption of morphine and / or NOA within 24 hours before surgery
- •Absorption of methadone within 48 hours before surgery
- •History of epilepsy
- •Renal insufficiency (creatinin clearance <30 ml / min MDRD)
- •Hepatic insufficiency
- •Severe respiratory insufficiency
- •Pregnancy or breastfeeding women
- •History of seizures
- •Symptomatic urethroprostatic disorders
- •Angle-closure glaucoma
- •Gastrointestinal, cerebrovascular or other evolving bleedings
- •Active peptic ulcer or active gastritis
- •Severe heart failure
- •History of asthma triggered by taking ketoprofen or similar substances
- •Disable adult person under guardianship
- •Use of nitrous oxide during anesthesia protocol
研究组 & 干预措施
Control group C: Placebo
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Morphine (Drug)
Group P: Paracetamol
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Paracetamol (Drug)
Group P: Paracetamol
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Morphine (Drug)
Group N: Nefopam
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Nefopam (Drug)
Group N: Nefopam
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Morphine (Drug)
Group K: Ketoprofen
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Ketoprofen (Drug)
Group K: Ketoprofen
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Morphine (Drug)
Group PN: paracetamol and nefopam
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Paracetamol (Drug)
Group PN: paracetamol and nefopam
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Nefopam (Drug)
Group PN: paracetamol and nefopam
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Morphine (Drug)
Group PK: paracetamol and ketoprofen
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Paracetamol (Drug)
Group PK: paracetamol and ketoprofen
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Ketoprofen (Drug)
Group PK: paracetamol and ketoprofen
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Morphine (Drug)
Group NK: nefopam and ketoprofen
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Nefopam (Drug)
Group NK: nefopam and ketoprofen
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Ketoprofen (Drug)
Group NK: nefopam and ketoprofen
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Morphine (Drug)
Group PNK: paracetamol, nefopam and ketoprofen
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Paracetamol (Drug)
Group PNK: paracetamol, nefopam and ketoprofen
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Ketoprofen (Drug)
Group PNK: paracetamol, nefopam and ketoprofen
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Nefopam (Drug)
Group PNK: paracetamol, nefopam and ketoprofen
All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
干预措施: Morphine (Drug)
结局指标
主要结局
Morphine consumption (mg), accumulated over 24 hours, measured by patient controlled analgesia (PCA).
时间窗: Day 1
次要结局
- Incidence of side effects associated with morphine: nausea, vomiting, sedation, urinary retention, pruritus.(Day 3)
- Global satisfaction (measured after treatment)(Day 3)
- Morphine consumption (mg) measured by patient controlled analgesia (PCA).(Day 2, day 3)
- Incidence of chronic pain assessed by a telephone questionnaire 3 months after surgery (sub-study in 3 centers).(Month 3)
- Area of hyperalgesia measured using a von Frey filament expressed in cm2, 48 hours after surgery (sub-study in 3 centers).(Day 2)